Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
News and updates for Precision BioSciences, Inc. (Nasdaq: DTIL) center on its progress as a clinical stage gene editing company using the ARCUS platform to develop in vivo therapies for serious genetic and infectious diseases. Company announcements frequently highlight developments in its pipeline, clinical trial milestones, scientific publications, and capital markets activity.
A major focus of Precision’s news flow is PBGENE-HBV, the company’s wholly owned in vivo gene editing program for chronic hepatitis B. Updates include data from the global ELIMINATE-B trial, covering safety, dose-dependent antiviral activity, reductions in hepatitis B surface antigen (HBsAg), and biopsy evidence of ARCUS-mediated viral DNA editing. Press releases also describe regulatory designations such as Breakthrough Therapy status and the expansion of clinical trial sites across multiple countries.
Another recurring theme is PBGENE-DMD, a muscle-targeted excision program for Duchenne muscular dystrophy. News items discuss preclinical data on dystrophin restoration and functional muscle improvement, preparations for investigational new drug (IND) submissions, and plans for Phase 1/2 clinical studies in DMD patients with mutations in exons 45–55 of the dystrophin gene.
Investors can also find updates on partnered in vivo programs, such as ECUR-506 for neonatal onset OTC deficiency developed by iECURE using a licensed ARCUS nuclease, along with regulatory milestones like RMAT designation. Additional coverage includes progress in non-core ex vivo programs such as azer-cel, an allogeneic CAR T therapy being advanced by partners for lymphoma and autoimmune diseases.
Financial and corporate news, including quarterly results, equity offerings, and strategic priorities, round out the DTIL news stream. For those tracking gene editing, hepatitis B, DMD, and ARCUS-based therapies, this page provides an organized view of Precision BioSciences’ latest disclosures and clinical developments over time.
Precision BioSciences, Inc. (Nasdaq: DTIL) announces the appointment of Dr. Stanley R. Frankel as a Director and member of the Science and Technology Committee. Dr. Frankel, a seasoned hematologist-oncologist, brings extensive experience in immuno-oncology and cellular therapies, having led programs for multiple FDA-approved drugs. His leadership is expected to aid Precision in advancing its CAR T and gene correction therapies. Dr. Tony Yao will continue his board term until May 10, 2021, after supporting the company through its transition to a public entity.
Precision BioSciences Inc. (Nasdaq: DTIL) announced that Dr. Derek Jantz, Chief Scientific Officer and Co-Founder, will participate in a fireside chat at the Truist Securities 2021 Life Sciences Virtual Series.
Event Details:
Date: April 13, 2021
Time: 11:00 AM ET
A live webcast will be available on the company's website under the Investors & Media section, with a replay for approximately 30 days following the event.
Precision BioSciences focuses on developing innovative therapies using its proprietary ARCUS® genome editing platform.
Precision BioSciences (Nasdaq: DTIL) announced a transition plan to recruit a new Chief Executive Officer, with current CEO Matt Kane remaining in his role until a successor is found. The management team aims to advance CAR T programs, direct research against specific gene targets, and validate gene editing initiatives. While thanking Kane for his contributions, the board emphasizes the importance of identifying a leader to navigate the company's next growth phase and maximize opportunities within the ARCUS platform.
Precision BioSciences (Nasdaq: DTIL) announced its participation in the Guggenheim Healthcare Talks 2021 on April 1, 2021, focusing on genomic medicines and rare diseases. Dr. Derek Jantz, Chief Scientific Officer, will present on advancements in genomic medicine and cell therapy for dyslipidemia and Type 1 diabetes mellitus. The presentation will take place from 8:00-8:50 AM ET and will be accessible via a live webcast on the company's website, with an archived replay available for 30 days.
Precision BioSciences (NASDAQ: DTIL) reported a pivotal 2020, achieving significant advancements in its ARCUS genome editing and CAR T programs. The company announced a collaboration with Eli Lilly for developing gene therapies, receiving $100 million upfront. Financially, total revenues rose to $24.3 million, while R&D expenses increased to $98.1 million, reflecting growth in clinical programs. However, the net loss widened to $109 million, or $(2.09) per share. Key milestones for 2021 include initiating the PBCAR19B clinical trial and reporting interim data for multiple CAR T programs.
Precision BioSciences, Inc. (Nasdaq: DTIL) will release its fourth quarter and fiscal year 2020 financial results and a business update on March 18, 2021. The company focuses on improving lives through its ARCUS® genome editing platform, which enables the development of CAR T immunotherapy clinical candidates and gene correction therapies. These advancements aim to address genetic and infectious diseases lacking adequate treatment options. For more information, visit www.precisionbiosciences.com.
Precision BioSciences (Nasdaq: DTIL) announced participation in two upcoming virtual investor conferences on March 9, 2021. The first is the H.C. Wainwright Global Life Sciences Conference, featuring an on-demand fireside chat starting at 7:00 AM ET. The second is the Barclays Global Healthcare Conference, with a presentation scheduled for 10:55 AM ET. Both events will be accessible via the company's website, ensuring investors can stay informed.
Precision BioSciences (Nasdaq: DTIL) announced a significant publication in Molecular Therapy detailing three-year follow-up results from a study on PCSK9 gene editing via its ARCUS® platform.
The study demonstrated a long-term reduction of LDL cholesterol levels by up to 56% in nonhuman primates after a single treatment, with stable reductions in PCSK9 protein levels by 85%. This data supports the potential for a one-time therapeutic approach to familial hypercholesteremia and highlights the efficacy and safety of ARCUS technology.
Precision BioSciences (Nasdaq: DTIL), a clinical stage biotechnology company, announced its participation in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021, at 2:00 PM ET. A live webcast of the presentation will be available on the company’s website in the Investors & Media section. Precision BioSciences is focused on improving life through its proprietary ARCUS genome editing platform, which aims to develop CAR T immunotherapy and gene correction therapies for genetic and infectious diseases.
Precision BioSciences (Nasdaq: DTIL) announced a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering its PBCAR19B product candidate aimed at treating relapsed/refractory Non-Hodgkin Lymphoma (NHL). The patent will encompass genetically-modified human T cells utilizing Precision's ARCUS genome editing platform, with an expected expiration date in April 2040. PBCAR19B is designed to enhance CAR T cell persistence by reducing rejection from T cells and natural killer cells. The Phase 1 clinical study is anticipated to commence by mid-2021.
FAQ
What is the current stock price of Precision Biosciences (DTIL)?
What is the market cap of Precision Biosciences (DTIL)?
